bioihbjkbjnl/mcl2 huggingface dataset:
Mobilization With Movement in Carpal Tunnel Syndrome.
Condition: Pain, Chronic
MeSH terms: Carpal Tunnel Syndrome; Chronic Pain
Study type: Interventional

Summary: 
      Peripheral nerve impingement neuropathies are the most common mononeuropathies encountered in
      clinical practice. Carpal Tunnel Syndrome (CTS) occurs as a result of compression of the
      median nerve as it passes through the carpal tunnel, a narrow osteofibrous canal. CTS is the
      most common entrapment neuropathy of the upper extremity, affecting approximately 3% of the
      general population.

      Massage and mobilization techniques are used in the treatment of CTS due to their analgesic
      effects. The painless mobilization with movement technique (MWM, developed by Brian Mulligan)
      is a manual therapy method applies to correct the limitation of movement in the joint and to
      relieve pain and functional disorders. Many studies have shown that MWM technique provides
      faster and momentary painless joint movement compared to other physical therapy modalities.

      The patient group with CTS has a large place in the general population and long treatment
      processes cause both labour loss and economic loss. In the literature review, there is no
      study examining the effects of MWM in patients with CTS. Therefore, this study aimed to
      examine the effectiveness of MWM technique in cases with CTS.
    

Detailed description: 
      In this study, 45 CTS patients with age range 18-65 who applied to Kırşehir Ahi Evran
      University Training and Research Hospital were examined. The individuals included in the
      study were divided into two groups according to the paired randomization method. These groups
      were control and intervention groups. Traditional physiotherapy methods were applied to the
      control group, traditional physiotherapy and MWM techniques were applied to the intervention
      group. Traditional physiotherapy methods were included; Transcutaneous Electrical Nerve
      Stimulation (TENS), Ultrasound (US), tendon-nerve gliding exercises, night splint, stretching
      and strengthening exercises.

      For the evaluation of patients; Visual Analogue Scale (VAS), wrist goniometric measurements,
      grip strength measurement, pinch strength measurement, edema measurement, Electromyography
      (EMG), Nelson Hand Reaction Test, Upper Limb Disorders Arm Shoulder and Hand Problems
      Questionnaire (DASH), Boston Carpal The Tunnel Injury Questionnaire and Michigan Hand Result
      Questionnaire (MHRQ) was used.
    

Intervention name(s): TENS, US, exercise
Intervention type(s): Other
Intervention description(s): Physiotherapy
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: Randomized Controlled Trial
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Pain; Mobilisation
Muscle Strength, Functional Capacity, Respiratory Function and Quality Of Life In Cystic Fibrosis Patients
Condition: Cystic Fibrosis; Muscle Strength; Pulmonary Function; Functional Capacity; Exercise Tolerance; Muscular Endurance
MeSH terms: Cystic Fibrosis; Fibrosis
Study type: Interventional

Summary: 
      This study was designed to investigate the relationship between upper extremity muscle
      strength and endurance, functional capacity, and quality of life child and adolescent with
      cystic fibrosis
    

Detailed description: 
      Child and adolescent with cystic fibrosis patients were assessed for upper extremity muscle
      strength and (Shoulder abductors muscle strength, Elbow flexion muscle strength, Handgrip
      strength) muscular endurance(arm pull-up test), lung function test, and functional capacity
      (six-minute walk test distance), and Quality Of Life (Cystic Fibrosis Questionnaire-Revised)
    

Intervention name(s): cystic fibrosis
Intervention type(s): Other
Intervention description(s): Evaluation of Upper Extremity Muscle Strength and Endurance, functional capacity, Respiratory Function and Quality of Life
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Other
Keywords: muscle strength; pulmonary function; Cystic Fibrosis; functional capacity
The Effect of Training on Hemodynamic Factors in Ballet Dancer
Condition: Venous Insufficiency; Foot Drop (Acquired)
MeSH terms: Peroneal Neuropathies; Venous Insufficiency
Study type: Observational

Summary: 
      Classic ballet dance is a demonstration of complex motor skills to be revealed in aesthetic
      combinations and repetitively, and it demands intensive use of the lower extremities within
      extreme of range of motion (ROM). Because ballet practice depends on advanced technical
      skills, it involves intensive physical training and causes an overload on the musculoskeletal
      system and foot deformities such as pes planus.

      Plantar venous pump (PVP) is a network of multiple venous vessels located between the muscles
      of the foot arch. PVP is considered the first step of venous return and discharges into the
      posterior tibial vein (PTV). PVP is reported to be active during gait while it is inactive in
      resting position. There are different views on the mechanisms enabling its activation 1-3.
      The general view is that during the stance phase of the gait, the flattening of the plantar
      arch with weight transfer causes the veins in this region to narrow and creates a force that
      pumps the blood up.

      The aim of this study is the investigation what kind of hemodynamic changes ballet training
      causes in the lower extremity
    


Intervention name(s): Navicular drop measurement; Measurement of venous return parameters in supine; Measurement of venous return parameters in standing; measurement of midfoot pressure distrubition
Intervention type(s): Other; Other; Other; Other
Intervention description(s): The difference in navicular height between sitting and standing positions was recorded (mm) as the amount of navicular drop.; Venous return parameters of posterior tibial vein was measured when participant applied force equivalent to their own body weight on plantar surface of their right leg in supine position; In standing, venous return parameters was measured of posterior tibial vein when participants shift all of their weight to the right leg for 3 second with their leg muscles as relaxed as possible and their knee joint in full extension.; In standing, midfoot pressure distrubution was measured when participants shift all of their weight to the right leg
Observational model: Other
Time perspective: Cross-Sectional
Sampling method: Probability Sample
Study population: 
        Ballerinas taking ballet training at least for 4 years and female sedentary students
Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients
Condition: HIV Infections
MeSH terms: HIV Infections
Study type: Interventional
Phase: Phase 4

Summary: 
      The purpose of this study is to provide long-term clinical safety and efficacy data for
      tenofovir disoproxil fumarate and emtricitabine in HIV-infected patients experiencing various
      degrees of renal impairment.
    

Detailed description: 
      The primary objective of this study is as follows:

        -  To evaluate the safety and tolerability of tenofovir following administration of
           tenofovir disoproxil fumarate 300 mg for 48 weeks in HIV-infected patients experiencing
           various degrees of renal impairment.

      The secondary objectives of this study are as follows:

        -  To evaluate the safety and tolerability of emtricitabine following administration of
           emtricitabine 200 mg for 48 weeks in HIV-infected patients experiencing various degrees
           of renal impairment.

        -  To evaluate the efficacy of tenofovir disoproxil fumarate in combination with
           emtricitabine in renally-impaired HIV-infected patients.

        -  To evaluate the pharmacokinetics of tenofovir and emtricitabine in renally-impaired
           HIV-infected patients.
    

Intervention name(s): Truvada (tenofovir DF + emtricitabine); Emtriva (emtricitabine); Viread (tenofovir DF)
Intervention type(s): Drug; Drug; Drug
Intervention MeSH terms: Tenofovir; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: HIV-1; Treatment Naive; Treatment Experienced
Extracorporeal CO2 Removal in COPD Exacerbation
Condition: COPD Exacerbation
MeSH terms: Pulmonary Disease, Chronic Obstructive
Study type: Interventional
Phase: Phase 2

Summary: 
      The minimally invasive extracorporeal carbon dioxide removal may decrease the respiratory
      load during chronic obstructive pulmonary disease (COPD) exacerbation, reducing the need to
      advance the respiratory care toward invasive mechanical ventilation in patients refractory to
      non-invasive ventilatory support (NIV), or decreasing the need of ventilatory support in
      patients already invasively ventilated, thereby accelerating the weaning process.

      The investigators intend to perform a multi-center experimental non randomized single arm
      prospective study to investigate the efficacy of the Decap Smart in reducing the intubation
      rate or the duration of invasive mechanical ventilation in patients with COPD treated either
      with NIV or invasive mechanical ventilation (IMV) for severe respiratory failure and
      hypercapnia. The results of the study will be compared to the data available in the
      literature.
    


Intervention name(s): minimally invasive extracorporeal carbon dioxide removal
Intervention type(s): Device
Intervention description(s): The application of the extracorporeal carbon dioxide removal will be initiated by using a modified continuous veno-venous hemofiltration system equipped with a membrane lung with a total membrane surface of 1,35 m2 (Decap® Smart).
Femoral vein is accessed via a double lumen catheter (14 F) inserted with the Seldinger technique and connected with the extracorporeal circuit. Blood flow is driven through the circuit by a roller nonocclusive low-flow pump (0- 450 ml/min) through a membrane lung (Euroset) that is connected to a fresh gas flow source delivering 100% oxygen at a constant rate of 8 l/min. Exiting the membrane lung, blood is driven to a hemofilter (Medica D250). The resulting plasmatic water is recirculated through the membrane lung by a peristaltic pump (0-155 ml/min).
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Supportive Care
Keywords: COPD
Impact of Oral Dyglomera™ on Body Fat and Blood Lipids of Overweight and Obese Adults
Condition: Body Fat Disorder
MeSH terms: Overweight
Study type: Interventional

Summary: 
      The extract of Dichrostachys glomerata (DyglomeraTM), has been reported to be effective in
      weight reduction in obese patients with metabolic syndrome. This plant has been shown to have
      many biological properties and has been reported to have no toxic or adverse side effects in
      animals. The purpose of this human study was to prove that the effect of reducing body fat
      percentage (%) after 12 weeks of intake was superior to that of the control group.
    

Detailed description: 
      This is a 12-weeks randomized double-blind placebo controlled trial. 120 number of subjects
      are planned. Each subject will be administered a single dose of the investigational product
      once daily, before lunch or dinner, consisting each time of 400 mg of the test product or
      placebo. Subjects will be assigned to the test group or placebo group in random order.
      Evaluations will be taken at baseline and at the beginning of each of the 5 study visits.

      Screening data will be reviewed to determine subject eligibility. Subjects who meet all
      inclusion criteria and none of the exclusion criteria will be entered into the study.

      The following investigational products will be used:

        -  Test product: Dichrostachys glomerata extract (Dyglomera™) at a dose of 400 mg

        -  Control product: Placebo at a dose of 400 mg In this human study, starting with Visit 2,
           the duration of participation in the human study will be 12 weeks (84 days) in total.
           The study period will be planned to be 8 months from the date of approval of the human
           study. The screening visit of the first subject will be conducted at the MAX SPECIALTY
           HOSPITAL, and the first subject will be enrolled thereafter. The last subject will
           complete the study within about 5 months.
    

Intervention name(s): Oral Dyglomera
Intervention type(s): Dietary Supplement
Intervention description(s): Measurement of body weight, waist circumference, hip circumference, waist to hip ratio, body mass index, body fat.
Blood draw and measurement of blood total Cholesterol, HDL-cholesterol, LDL-cholesterol), ALT, AST, Fasting Blood Glucose, CRP, adiponectin, and leptin.
Other intervention name(s): Placebo
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: 12-week randomized, double-blind, placebo-controlled trial with subjects administered 400 mg per day of Dyglomera
Masking: Double (Participant, Care Provider)
Primary purpose: Treatment
Keywords: Body fat; Dyglomera; Blood lipids
Copeptin in the Differential Diagnosis of Dysnatremia in Hospitalized Patients
Condition: Hyponatremia; Hypernatremia
MeSH terms: Hyponatremia; Hypernatremia
Study type: Observational

Summary: 
      Background: Hypo- and hypernatremia are common in hospitalized patients. The differential
      diagnosis of dysnatremia is challenging.

      Osmotically inadequate secretion of antidiuretic hormone (ADH) is the predominant mechanism
      in most dysnatremic disorders. ADH measurement is cumbersome. It is derived from a larger
      precursor peptide along with copeptin, which is a more stable peptide directly mirroring the
      production of ADH.

      Objective: To evaluate the additional value of copeptin to improve a currently used algorithm
      in the differential diagnosis of (A) severe hypoosmolar hypo- and (B) severe hypernatremia.

      Design: Prospective observational study.
    


Observational model: Cohort
Time perspective: Prospective
Sampling method: Probability Sample
Study population: 
        hospitalized patients with severe hypo or hypernatremia
      
Keywords: hyponatremia; hypernatremia
A Four-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol Once a Day 100, 200 and 300 mg Versus Placebo for the Treatment of Pain Due to Osteoarthritis of the Knee
Condition: Pain; Osteoarthritis, Knee
MeSH terms: Osteoarthritis; Osteoarthritis, Knee
Study type: Interventional
Phase: Phase 3

Summary: 
      The purpose of this study is to compare the analgesic efficacy and safety of Tramadol Once a
      Day 100, 200, 300 mg and Placebo
    


Intervention name(s): Tramadol Once A Day; Placebo
Intervention type(s): Drug; Drug
Intervention description(s): One Tramadol Once A Day tablet at randomized dose daily.; One Placebo tablet daily.
Intervention MeSH terms: Tramadol
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of a Vaccine Against Essential Hypertension
Condition: Hypertension
MeSH terms: Hypertension; Essential Hypertension
Study type: Interventional
Phase: Phase 2

Summary: 
      CYT006-AngQb is a vaccine that induces a B-cell mediated immune response characterized by the
      generation of specific antibodies (IgG and IgM) against Angiotensin II. The vaccine is
      administered by subcutaneous injection.

      The objectives of the study are:

        -  To evaluate safety and tolerability of 5 s.c. injections of 300µg CYT006-AngQb with
           Alhydrogel™ in patients with mild to moderate essential hypertension (hypertension Grade
           I and II).

        -  To assess pharmacodynamic effects, i.e. anti-Ang II immune response and renin-
           angiotensin system (RAS) biomarkers.

        -  To explore the effect on blood pressure using ABPM.
    


Intervention name(s): CYT006-AngQb; Placebo
Intervention type(s): Biological; Biological
Intervention description(s): s.c.; s.c.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: mild essential hypertension; moderate essential hypertension
ECG Belt vs. Echocardiographic Optimization of CRT
Condition: Heart Failure, Systolic
MeSH terms: Heart Failure; Heart Failure, Systolic
Study type: Interventional

Summary: 
      Cardiac resynchronization therapy (CRT) has been a valuable intervention for patients with
      systolic heart failure for over 15 years. Despite years of research, there is a still a
      25-40% non-responder rate depending on the outcomes measured. CRT optimization is a term used
      to describe the act of individualizing the therapy (CRT programming) for an individual
      patient. This is not often performed, but when it is, echocardiography is utilized. Recent
      work of body surface mapping using a novel system called the ECG Belt has shown a
      relationship between measures of electrical dyssynchrony and acute and chronic heart pumping
      function. This study will compare outcomes of patients randomized to either echocardiographic
      or ECG Belt optimization of CRT devices.
    

Detailed description: 
      This is a prospective randomized study designed to determine whether cardiac
      resynchronization therapy (CRT) device programming guided by the ECG Belt (Medtronic, PLC)
      improves echocardiographic and functional outcomes in heart failure (HF) patients. The
      population will include patients treated with CRT for standard indications (not implanted for
      the sole purposes of this study). The study will focus enrollment on patients who do not have
      baseline characteristics predicting the best CRT response. Therefore the study will not
      enroll patients having non-ischemic HF etiology, left bundle branch (LBBB) morphology, and
      QRSd > 150 ms or those previously RV paced.
    

Intervention name(s): Optimization of CRT Device
Intervention type(s): Diagnostic Test
Intervention description(s): Use a body surface mapping system to quantify electrical dyssynchrony or echocardiography to quantify diastolic blood flow characteristics. Program the pacemaker to maximize the benefit of the modality the subject is randomized to.
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: 1:1 randomization
Masking: Single (Outcomes Assessor)
Primary purpose: Treatment
Keywords: cardiac resynchronization therapy; pacing; echocardiography; optimization; heart failure
Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of HSD-016
Condition: Healthy Subjects
Study type: Interventional
Phase: Phase 1

Summary: 
      This is a single ascending dose study of HSD-016 to provide the initial assessment of the
      safety, tolerability, how the drug is absorbed and eliminated, and it's effect on the body in
      Japanese male subjects.
    


Intervention name(s): HSD-016; placebo
Intervention type(s): Drug; Drug
Allocation: Randomized
Intervention model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children
Condition: Nonalcoholic Fatty Liver Disease (NAFLD)
MeSH terms: Liver Diseases; Fatty Liver; Non-alcoholic Fatty Liver Disease
Study type: Interventional
Phase: Phase 2/Phase 3

Summary: 
      CyNCh is a multi-center, placebo-controlled clinical trial of children ages 8 to 17 years
      with biopsy-confirmed moderate to severe nonalcoholic fatty liver disease (NAFLD). The
      primary objective is to evaluate whether 52 weeks of treatment with cysteamine bitartrate
      delayed-release capsules will result in improvement in liver disease severity.
    


Intervention name(s): DR cysteamine bitartrate capsule; DR cysteamine bitartrate placebo
Intervention type(s): Drug; Other
Intervention description(s): 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients >65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients >80 kg at baseline; 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients >65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients >80 kg at baseline
Other intervention name(s): cysteamine bitartrate delayed-release
Intervention MeSH terms: Cysteamine
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Treatment
Keywords: Nonalcoholic Fatty Liver Disease (NAFLD); Cysteamine bitartrate delayed release; Children
Single-centre, Registry Trial, the Patients Presented With Stable Coronary Artery Disease
Condition: Coronary Artery Disease
MeSH terms: Coronary Artery Disease; Myocardial Ischemia; Coronary Disease
Study type: Observational [Patient Registry]

Summary: 
      This is a prospective study to analyze the outcome of provisional main vessel stenting on
      side branch by utilizing Two-Dimensional (2D) and Three-Dimensional (3D) frequency domain
      optical coherence tomography (FD-OCT). To analyze the fate of side-branch after provisional
      main vessel stenting based on morphology defined prior to PCI by OCT. Offline analysis of
      side branch impingement of the ostium of SB leading to acute loss in SB diameter area, carina
      shift and plaque shift will be also be performed.
    

Detailed description: 
      Patients with stable coronary artery disease with angiographic main vessel lesion not
      involving side branch (SB) in whom provisional stenting strategy is planned will be
      recruited. All the participants of the registry will receive same stent. OCT will be
      performed to analyze plaque morphology, SB size, SB angle and side branch ostial involvement.
    

Observational model: Cohort
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        Patients with stable coronary artery disease with angiographic main vessel lesion not
        involving side branch (SB) in whom provisional stenting strategy is planned
      
Keywords: CAD
Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia
Condition: Schizophrenia
MeSH terms: Schizophrenia
Study type: Interventional

Summary: 
      This study will determine whether eszopiclone will normalize sleep patterns and restore
      sleep-dependent enhancement of motor skill learning in patients with schizophrenia. The
      investigators will compare subjects taking a placebo to those taking 3 mg of eszopiclone with
      regard to: sleep architecture and sleep latency as measured by actigraphy and polysomnography
      and sleep-dependent motor skill learning.
    


Intervention name(s): eszopiclone; placebo
Intervention type(s): Drug; Drug
Intervention description(s): 3 mg of eszopiclone at bedtime on two consecutive nights; Placebo capsules looking identical to eszopiclone at bedtime on two consecutive nights
Other intervention name(s): Lunesta
Intervention MeSH terms: Eszopiclone
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Keywords: sleep; schizophrenia; procedural learning; motor skill